Lactobacillus taiwanensis BCRC17755 alleviates motor dysfunction and dopaminergic neuronal loss in mouse models of Parkinsonâs disease
äºBeneficial MicrobesSearch for other papers by Y. Choi in
Current site
Google Scholar
Current address: Mthera Pharma Co., 38 Magokjungang 8-ro, Gangseo-gu, Seoul 07793, South Korea
Search for other papers by J.G. Choi in
Current site
Google Scholar
Current address: Department of Formulae Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujung-Gu, Seongnam 13120, South Korea
Search for other papers by E. Huh in
Current site
Google Scholar
Current address: Department of Food and Nutrition, Chung-Ang University, Anseong, 17546, South Korea
Search for other papers by H. Eo in
Current site
Google Scholar
Search for other papers by Y.-J. Shin in
Current site
Google Scholar
Search for other papers by M.G. Park in
Current site
Google Scholar
Search for other papers by D.-H. Kim in
Current site
Google Scholar
Department of Oriental Pharmaceutical Science and Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, South Korea
Neurobiota Research Center, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, South Korea
Search for other papers by M.S. Oh in
Current site
Google Scholar
Abstract
Parkinsonâs disease (PD) is a complex progressive neurodegenerative disease characterized by both motor and nonmotor symptoms such as constipation and dyspepsia. Recently, growing evidence has suggested that a specific gut microbiome is associated with the pathophysiology of PD through the microbiota-gut-brain axis. We previously discovered that Proteus mirabilis induced motor impairment and brain dopaminergic neurodegeneration in normal mice. In this context, exploring beneficial microbe would be reasonable strategy to treat PD fundamentally. With that the current study aimed to evaluate whether Lactobacillus taiwanensis BCRC17755 (BCRC17755) could ameliorate PD pathologies induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and P. mirabilis in mice. To demonstrate this, we measured motor function by performing pole test and the rotarod test and conducted histological analysis to assess the changes of factors in both brain and the gut. As a result, BCRC17755 decreased faecal abundance of P. mirabilis, which was higher in both the MPTP and P. mirabilis-treated mice. Additionally, BCRC17755 improved the motor deficits and alleviated damage to nigrostriatal dopaminergic neurons observed in both MPTP and P. mirabilis-induced PD mice. Furthermore, BCRC17755 mitigated microglial hyperactivation triggered by MPTP and P. mirabilis in the substantia nigra pars compacta and striatum of mice. Similarly, the release of inflammatory cytokines, including interleukin-1 beta and tumor necrosis factor alpha, was suppressed following the administration of BCRC17755 in the colon. Taken together, all the results suggest that BCRC17755 is a beneficial microbe for the treatment of PD by inhibiting the P. mirabilis growth.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Aktas, B., 2023. Gut microbial alteration in MPTP mouse model of Parkinson disease is administration regimen dependent. Cellular and Molecular Neurobiology 43: 2815-2829. https://doi.org/10.1007/s10571-023-01319-7
-
Alvarez-Sieiro, P., Montalban-Lopez, M., Mu, D. and Kuipers, O.P., 2016. Bacteriocins of lactic acid bacteria: extending the family. Applied Microbiology and Biotechnology 100: 2939-2951. https://doi.org/10.1007/s00253-016-7343-9
-
Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S.A., Caccialanza, R., Pezzoli, G. and Cereda, E., 2016. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology 87: 1274-1280. https://doi.org/10.1212/WNL.0000000000003127
-
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D. and Rüb, U., 2002. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinsonâs disease (preclinical and clinical stages). Journal of Neurology 249(Suppl. 3): III/1-III/5. https://doi.org/10.1007/s00415-002-1301-4
-
Cassani, E., Privitera, G., Pezzoli, G., Pusani, C., Madio, C., Iorio, L. and Barichella, M., 2011. Use of probiotics for the treatment of constipation in Parkinsonâs disease patients. Minerva Gastroenterology Dietology 57: 117-121.
-
Castelli, V., dâAngelo, M., Lombardi, F., Alfonsetti, M., Antonosante, A., Catanesi, M., Benedetti, E., Palumbo, P., Cifone, M.G., Giordano, A., Desideri, G. and Cimini, A., 2020. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinsonâs disease models. Aging 12: 4641-4659. https://doi.org/10.18632/aging.102927
-
Chen, S.G., Stribinskis, V., Rane, M.J., Demuth, D.R., Gozal, E., Roberts, A.M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., Son, F., Jin, S., Kerber, R., Adame, A., Masliah, E. and Friedland, R.P., 2016. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged fischer 344 rats and caenorhabditis elegans. Science Reports 6: 34477. https://doi.org/10.1038/srep34477
-
Choi, J.G., Kim, N., Ju, I.G., Eo, H., Lim, S.M., Jang, S.E., Kim, D.H. and Oh, M.S., 2018. Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice. Science Reports 8: 1275. https://doi.org/10.1038/s41598-018-19646-x
-
Chu, C., Yu, L., Li, Y., Guo, H., Zhai, Q., Chen, W. and Tian, F., 2023. Lactobacillus plantarum CCFM405 against rotenone-induced Parkinsonâs disease mice via regulating gut microbiota and branched-chain amino acids biosynthesis. Nutrients 15. https://doi.org/10.3390/nu15071737
-
Cryan, J.F., OâRiordan, K.J., Cowan, C.S.M., Sandhu, K.V., Bastiaanssen, T.F.S., Boehme, M., Codagnone, M.G., Cussotto, S., Fulling, C., Golubeva, A.V., Guzzetta, K.E., Jaggar, M., Long-Smith, C.M., Lyte, J.M., Martin, J.A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., OâConnor, R., Cruz-Pereira, J.S., Peterson, V.L., Rea, K., Ritz, N.L., Sherwin, E., Spichak, S., Teichman, E.M., van de Wouw, M., Ventura-Silva, A.P., Wallace-Fitzsimons, S.E., Hyland, N., Clarke, G. and Dinan, T.G., 2019. The microbiota-gut-brain axis. Physiology Reviews 99: 1877-2013. https://doi.org/10.1152/physrev.00018.2018
-
Eo, H., Kwon, Y., Huh, E., Sim, Y., Choi, J.G., Jeong, J.S., Du, X.F., Soh, H.Y., Hong, S.P., Kim Pak, Y. and Oh, M.S., 2019. Protective effects of DA-9805 on dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity in the models of Parkinsonâs disease. Biomedical Pharmacotherapy 117: 109184. https://doi.org/10.1016/j.biopha.2019.109184
-
Grazul, H., Kanda, L.L. and Gondek, D., 2016. Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice. Gut Microbes 7: 101-114. https://doi.org/10.1080/19490976.2016.1138197
-
Guo, T. and Chen, L., 2022. Gut microbiota and inflammation in Parkinsonâs disease: Pathogenetic and therapeutic insights. European Journal of Inflammation 20. https://doi.org/10.1177/1721727x221083763
-
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.Y., Roybon, L., Melki, R. and Li, J.Y., 2014. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathologica 128: 805-820. https://doi.org/10.1007/s00401-014-1343-6
-
Horsager, J., Andersen, K.B., Knudsen, K., Skjærbæk, C., Fedorova, T.D., Okkels, N., Schaeffer, E., Bonkat, S.K., Geday, J., Otto, M., Sommerauer, M., Danielsen, E.H., Bech, E., Kraft, J., Munk, O.L., Hansen, S.D., Pavese, N., Göder, R., Brooks, D.J., Berg, D. and Borghammer, P., 2020. Brain-first versus body-first Parkinsonâs disease: a multimodal imaging case-control study. Brain 143: 3077-3088. https://doi.org/10.1093/brain/awaa238
-
Houser, M.C., Chang, J., Factor, S.A., Molho, E.S., Zabetian, C.P., Hill-Burns, E.M., Payami, H., Hertzberg, V.S. and Tansey, M.G., 2018. Stool immune profiles evince gastrointestinal inflammation in Parkinsonâs disease. Movement Disorders 33: 793-804. https://doi.org/10.1002/mds.27326
-
Hsieh, T.H., Kuo, C.W., Hsieh, K.H., Shieh, M.J., Peng, C.W., Chen, Y.C., Chang, Y.L., Huang, Y.Z., Chen, C.C., Chang, P.K., Chen, K.Y. and Chen, H.Y., 2020. Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinsonâs disease. Brain Science 10. https://doi.org/10.3390/brainsci10040206
-
Huh, E., Choi, J.G., Choi, Y., Ju, I.G., Kim, B., Shin, Y.J., An, J.M., Park, M.G., Yim, S.V., Chung, S.J., Seo, S.U., Kim, D., Kim, C.H., Kim, D.H. and Oh, M.S., 2023a. P. mirabilis-derived pore-forming haemolysin, HpmA drives intestinal alpha-synuclein aggregation in a mouse model of neurodegeneration. EBioMedicine 98: 104887. https://doi.org/10.1016/j.ebiom.2023.104887
-
Huh, E., Choi, J.G., Lee, M.Y., Kim, J.H., Choi, Y., Ju, I.G., Eo, H., Park, M.G., Kim, D.H., Park, H.J., Lee, C.H. and Oh, M.S., 2023b. Peripheral metabolic alterations associated with pathological manifestations of Parkinsonâs disease in gut-brain axis-based mouse model. Frontiers in Molecular Neuroscience 16: 1201073. https://doi.org/10.3389/fnmol.2023.1201073
-
Huh, E., Choi, J.G., Noh, D., Yoo, H.S., Ryu, J., Kim, N.J., Kim, H. and Oh, M.S., 2020. Ginger and 6-shogaol protect intestinal tight junction and enteric dopaminergic neurons against 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine in mice. Nutritional Neuroscience 23: 455-464. https://doi.org/10.1080/1028415X.2018.1520477
-
Kim, S.W., Ha, Y.J., Bang, K.H., Lee, S., Yeo, J.H., Yang, H.S., Kim, T.W., Lee, K.P. and Bang, W.Y., 2020. Potential of bacteriocins from Lactobacillus taiwanensis for producing bacterial ghosts as a next generation vaccine. Toxins 12. https://doi.org/10.3390/toxins12070432
-
Lawrence, A.D., Evans, A.H. and Lees, A.J., 2003. Compulsive use of dopamine replacement therapy in Parkinsonâs disease: reward systems gone awry? Lancet Neurology 2: 595-604. https://doi.org/10.1016/s1474-4422(03)00529-5
-
Li, T., Chu, C., Yu, L., Zhai, Q., Wang, S., Zhao, J., Zhang, H., Chen, W. and Tian, F., 2022. Neuroprotective effects of Bifidobacterium breve CCFM1067 in MPTP-induced mouse models of Parkinsonâs disease. Nutrients 14. https://doi.org/10.3390/nu14214678
-
Li, X.Y., Li, L.X., Li, Y., Zhou, R.C., Li, B., Gu, X., Fu, S.C., Jin, B.Y., Zuo, X.L. and Li, Y.Q., 2021. Complete genome sequencing of Peyerâs patches-derived Lactobacillus taiwanensis CLG01, a potential probiotic with antibacterial and immunomodulatory activity. BMC Microbiology 21: 68. https://doi.org/10.1186/s12866-021-02127-z
-
Lim, S.Y. and Tan, A.H., 2018. Historical perspective: The pros and cons of conventional outcome measures in Parkinsonâs disease. Parkinsonism Related Disorders 46(Suppl. 1): S47-S52. https://doi.org/10.1016/j.parkreldis.2017.07.029
-
Martinenghi, L.D. and Leisner, J.J., 2022. Scientistsâ assessments of research on lactic acid bacterial bacteriocins 1990-2010. Frontiers in Microbiology 13: 908336. https://doi.org/10.3389/fmicb.2022.908336
-
Morais, L.H., Schreiber, H.L.T. and Mazmanian, S.K., 2021. The gut microbiota-brain axis in behaviour and brain disorders. Nature Reviews Microbiology 19: 241-255. https://doi.org/10.1038/s41579-020-00460-0
-
Mudaliar, S.B., Poojary, S.S., Bharath Prasad, A.S. and Mazumder, N., 2024. Probiotics and paraprobiotics: effects on microbiota-gut-brain axis and their consequent potential in neuropsychiatric therapy. Probiotics Antimicrob Proteins. https://doi.org/10.1007/s12602-024-10214-6
-
Pu, Y., Chang, L., Qu, Y., Wang, S., Zhang, K. and Hashimoto, K., 2019. Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain. Aging (Albany NY) 11: 6915-6929. https://doi.org/10.18632/aging.102221
-
Qian, Y., Yang, X., Xu, S., Wu, C., Qin, N., Chen, S.D. and Xiao, Q., 2018. Detection of microbial 16S rRNA gene in the blood of patients with Parkinsonâs disease. Fronters in Aging Neuroscience 10: 156. https://doi.org/10.3389/fnagi.2018.00156
-
Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E., Challis, C., Schretter, C.E., Rocha, S., Gradinaru, V., Chesselet, M.F., Keshavarzian, A., Shannon, K.M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R. and Mazmanian, S.K., 2016. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinsonâs disease. Cell 167: 1469-1480, e1412. https://doi.org/10.1016/j.cell.2016.11.018
-
Solanki, R., Karande, A. and Ranganathan, P., 2023. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration. Frontiers Neurology 14: 1149618. https://doi.org/10.3389/fneur.2023.1149618
-
Sun, X., Feng, S., Qin, B., Ye, J., Xie, L., Gui, J. and Sang, M., 2024. Integrated multi-omics profiling highlights the benefits of resveratrol hydroxypropyl-β-cyclodextrin inclusion complex for A53T transgenic mice through the microbiota-gut-brain axis. Food & Function 15: 1489-1512. https://doi.org/10.1039/D3FO03667G
-
Tan, A.H., Lim, S.Y. and Lang, A.E., 2022. The microbiome-gut-brain axis in Parkinson disease â from basic research to the clinic. Nature Reviews Neurology 18: 476-495. https://doi.org/10.1038/s41582-022-00681-2
-
Wang, L., Zhao, Z., Zhao, L., Zhao, Y., Yang, G., Wang, C., Gao, L., Niu, C. and Li, S., 2022. Lactobacillus plantarum DP189 reduces alpha-SYN aggravation in MPTP-induced Parkinsonâs disease mice via regulating oxidative damage, inflammation, and gut microbiota disorder. Journal of Agriculture and Food Chemistry 70: 1163-1173. https://doi.org/10.1021/acs.jafc.1c07711
-
Wang, L.T., Kuo, H.P., Wu, Y.C., Tai, C.J. and Lee, F.L., 2009. Lactobacillus taiwanensis sp. nov., isolated from silage. International Journal of Systematic Evolution and Microbiology 59: 2064-2068. https://doi.org/10.1099/ijs.0.006783-0
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 925 | 425 | 18 |
| å ¨ææµè§æ¬¡æ° | 124 | 67 | 0 |
| PDFä¸è½½æ¬¡æ° | 305 | 184 | 0 |
Lactobacillus taiwanensis BCRC17755 alleviates motor dysfunction and dopaminergic neuronal loss in mouse models of Parkinsonâs disease
äºBeneficial MicrobesSearch for other papers by Y. Choi in
Current site
Google Scholar
PubMed
Current address: Mthera Pharma Co., 38 Magokjungang 8-ro, Gangseo-gu, Seoul 07793, South Korea
Search for other papers by J.G. Choi in
Current site
Google Scholar
PubMed
Current address: Department of Formulae Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujung-Gu, Seongnam 13120, South Korea
Search for other papers by E. Huh in
Current site
Google Scholar
PubMed
Current address: Department of Food and Nutrition, Chung-Ang University, Anseong, 17546, South Korea
Search for other papers by H. Eo in
Current site
Google Scholar
PubMed
Search for other papers by Y.-J. Shin in
Current site
Google Scholar
PubMed
Search for other papers by M.G. Park in
Current site
Google Scholar
PubMed
Search for other papers by D.-H. Kim in
Current site
Google Scholar
PubMed
Department of Oriental Pharmaceutical Science and Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, South Korea
Neurobiota Research Center, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, South Korea
Search for other papers by M.S. Oh in
Current site
Google Scholar
PubMed
Abstract
Parkinsonâs disease (PD) is a complex progressive neurodegenerative disease characterized by both motor and nonmotor symptoms such as constipation and dyspepsia. Recently, growing evidence has suggested that a specific gut microbiome is associated with the pathophysiology of PD through the microbiota-gut-brain axis. We previously discovered that Proteus mirabilis induced motor impairment and brain dopaminergic neurodegeneration in normal mice. In this context, exploring beneficial microbe would be reasonable strategy to treat PD fundamentally. With that the current study aimed to evaluate whether Lactobacillus taiwanensis BCRC17755 (BCRC17755) could ameliorate PD pathologies induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and P. mirabilis in mice. To demonstrate this, we measured motor function by performing pole test and the rotarod test and conducted histological analysis to assess the changes of factors in both brain and the gut. As a result, BCRC17755 decreased faecal abundance of P. mirabilis, which was higher in both the MPTP and P. mirabilis-treated mice. Additionally, BCRC17755 improved the motor deficits and alleviated damage to nigrostriatal dopaminergic neurons observed in both MPTP and P. mirabilis-induced PD mice. Furthermore, BCRC17755 mitigated microglial hyperactivation triggered by MPTP and P. mirabilis in the substantia nigra pars compacta and striatum of mice. Similarly, the release of inflammatory cytokines, including interleukin-1 beta and tumor necrosis factor alpha, was suppressed following the administration of BCRC17755 in the colon. Taken together, all the results suggest that BCRC17755 is a beneficial microbe for the treatment of PD by inhibiting the P. mirabilis growth.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 925 | 425 | 18 |
| å ¨ææµè§æ¬¡æ° | 124 | 67 | 0 |
| PDFä¸è½½æ¬¡æ° | 305 | 184 | 0 |
